# US 12,178,859 B2 · Anti inflammatory composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,178,859 B2
- Document ID: US12178859B2
- Status: Granted
- Kind: B2
- Application number: 17/423,066
- Filed: 2020-01-14
- Published: 2022-03-10
- Granted: 2024-12-31
- Earliest claimed: 2019-01-15
- Assignees: Wako Filter Technology Co., Ltd.; Teikyo University
- Applicants: Wako Filter Technology Co., Ltd.; Teikyo University
- Inventors: Hiroki Kageshima; Yoichi Murakami; Akira Saito; Shigeru Abe; Kazumi Hayama; Naho Maruyama
- Web page: https://patentgrep.com/patent/US12178859B2

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Y 302/01017: Lysozyme (3.2.1.17)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

The present invention provides a method for treating or preventing inflammation caused by neutrophils and a pharmaceutical composition for such treatment or prevention. Specifically, provided is a pharmaceutical composition or the like for treating or preventing inflammation caused by neutrophils that contains a complex in which lysozyme and chitosan are bonded.

## Claims

### Claim 1

A pharmaceutical composition for treating or preventing neutrophil-induced inflammation, comprising: decanoic acid and a complex of lysozyme and chitosan bound together, wherein the complex is contained at 0.01 mg/ml to 50 mg/ml in the pharmaceutical composition.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the chitosan is a water-soluble chitosan having a molecular weight of 1000 Da to 30,000 Da.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the complex is contained at 0.001% by mass to 5.0% by mass in the pharmaceutical composition.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising a terpene alcohol.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising a terpene alcohol, wherein the terpene alcohol is terpinen-4-ol, hinokitiol, or geraniol.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the neutrophil-induced inflammation is dermatitis or pyoderma.

### Claim 7

A method for treating or preventing neutrophil-induced inflammation, comprising a step of administering to a subject a pharmaceutical composition containing decanoic acid and a complex of lysozyme and chitosan bound together so as to suppress or prevent neutrophil-induced inflammation, wherein the complex is contained at 0.01 mg/ml to 50 mg/ml in the pharmaceutical composition.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the chitosan is a water-soluble chitosan having a molecular weight of 1000 Da to 30,000 Da.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the complex is contained at 0.001% by mass to 5.0% by mass in the pharmaceutical composition.

### Claim 10 (depends on 7)

The method according to claim 7, wherein the pharmaceutical composition further comprises a terpene alcohol.

### Claim 11 (depends on 7)

The method according to claim 7, wherein the pharmaceutical composition further comprises a terpene alcohol, wherein the terpene alcohol is terpinen-4-ol, hinokitiol, or geraniol.

### Claim 12 (depends on 7)

The method according to claim 7, wherein the neutrophil-induced inflammation is dermatitis or pyoderma.